RSV Vaccine 92% Effective Against Severe Outcomes in Adults Aged 60 and Older
A new report in Clinical Infectious Diseases found that the estimated effectiveness of the RSV vaccine against “respiratory illness and severe disease in adults aged 60 years and older was 92%.” CIDRAP has the news.
ACIP recommended that “all adults aged 75 and older and those aged 60 to 74 at high risk for severe RSV receive a single dose of the vaccine” in June 2024. Uptake has remained low, and by December, estimated U.S. coverage of RSV vaccines was only 34% among adults aged 75 and older.
The vast majority of participants in this study had chronic conditions, and 56.4% were aged 75 and older. The study also included “8,965 ED visits/hospitalizations for acute respiratory illness that included RSV testing. In total, 7.8% of patients were RSV-positive, among whom 0.3% had been vaccinated, compared with 3.6% of controls.” The vaccine effectiveness (VE) of the RSV patients with strict controls came out to 92%, and only lowered to 90% with the inclusion of broad controls.
The results indicate that the vaccine “has higher VE against severe outcomes than other current respiratory vaccines, including SARS-CoV-2, influenza, and pneumococcal vaccine.” Expansion of RSV vaccine recommendations to adults aged 50-59 remains “pending.”
About the Author
Matt MacKenzieMatt MacKenzie
Associate Editor
Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care.
Related
rsv_vaccine
rsv_vaccine